Literature DB >> 16467676

Intravitreal toxicity of moxifloxacin.

Erdinc Aydin1, Abdul Ahad Kazi, Gholam A Peyman, Mohammad Riazi Esfahani.   

Abstract

PURPOSE: To assess the retinal toxicity of various concentrations of intravitreally administered moxifloxacin, a fourth-generation fluoroquinolone.
METHODS: Ten New Zealand albino rabbits were divided into five groups. The initial concentration of moxifloxacin (400 mg/250 mL) was titrated using 5% dextrose solution to concentrations (320 microg/0.1 mL, 160 microg/0.1 mL, 100 microg/0.1 mL, and 50 microg/0.1 mL) that were injected intravitreally into 1 eye of each rabbit. Two control eyes were injected intravitreally with 0.1 mL of 5% dextrose solution. All animals were examined before and after injection by indirect ophthalmoscopy and slit-lamp biomicroscopy; electroretinography (ERG) was performed on all animals. The animals were killed, and their eyes were enucleated and examined with light microscopy.
RESULTS: Remarkable decreases in ERG findings were noted in the group injected with moxifloxacin at a concentration of 320 microg/0.1 mL. No meaningful ERG changes were observed in eyes injected with moxifloxacin at other concentrations. There were no signs of retinal toxicity during slit-lamp examination, indirect ophthalmoscopy, or light microscopy in any eyes injected with moxifloxacin concentrations of < or =160 microg/0.1 mL.
CONCLUSIONS: Intravitreal injection of moxifloxacin at a concentration of < or =160 microg/0.1 mL appeared nontoxic in the rabbit eye.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16467676     DOI: 10.1097/00006982-200602000-00011

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  11 in total

1.  Severe bacterial endophthalmitis: towards improving clinical outcomes.

Authors:  Billy D Novosad; Michelle C Callegan
Journal:  Expert Rev Ophthalmol       Date:  2010-10

2.  Evaluation of potential retinal toxicity of adalimumab (Humira).

Authors:  Miltiadis Tsilimbaris; Vasilios F Diakonis; Irini Naoumidi; Spyridon Charisis; Iraklis Kritikos; George Chatzithanasis; Thekla Papadaki; Sotiris Plainis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-03-19       Impact factor: 3.117

3.  [Intracameral moxifloxacin: a safe option for endophthalmitis prophylaxis? In vitro safety profile for intraocular application].

Authors:  M Kernt; C Hirneiss; A S Neubauer; R G Liegl; K H Eibl; A Wolf; H de Kaspar; M W Ulbig; A Kampik
Journal:  Ophthalmologe       Date:  2010-08       Impact factor: 1.059

4.  Retinal safety of a new fluoroquinolone, pradofloxacin, in cats: assessment with electroretinography.

Authors:  Andre Messias; Florian Gekeler; Alfred Wegener; Klaus Dietz; Konrad Kohler; Eberhart Zrenner
Journal:  Doc Ophthalmol       Date:  2007-10-02       Impact factor: 2.379

Review 5.  Pharmacokinetics of intravitreal antibiotics in endophthalmitis.

Authors:  Medikonda Radhika; Kopal Mithal; Abhishek Bawdekar; Vivek Dave; Animesh Jindal; Nidhi Relhan; Thomas Albini; Avinash Pathengay; Harry W Flynn
Journal:  J Ophthalmic Inflamm Infect       Date:  2014-09-10

6.  Moxifloxacin Concentration and Proteomic Analysis of Aqueous Humor in Human Uveitis Associated with Oral Moxifloxacin Therapy.

Authors:  David M Hinkle; Nicole A Kruh-Garcia; Jonathan N Kruh; Carolyn Broccardo; Priyanka Doctor; C Stephen Foster
Journal:  Open Ophthalmol J       Date:  2017-06-12

Review 7.  The Role of Systemic Antimicrobials in the Treatment of Endophthalmitis: A Review and an International Perspective.

Authors:  Andrzej Grzybowski; Magdalena Turczynowska; Stephen G Schwartz; Nidhi Relhan; Harry W Flynn
Journal:  Ophthalmol Ther       Date:  2020-07-01

8.  Toxicities of and inflammatory responses to moxifloxacin, cefuroxime, and vancomycin on retinal vascular cells.

Authors:  Hitomi Miyake; Dai Miyazaki; Yumiko Shimizu; Shin-Ichi Sasaki; Takashi Baba; Yoshitsugu Inoue; Kazuki Matsuura
Journal:  Sci Rep       Date:  2019-07-05       Impact factor: 4.379

9.  Intravitreal moxifloxacin in the management of Ochrobactrum intermedium endophthalmitis due to metallic intraocular foreign body.

Authors:  David J Jacobs; Thomas J Grube; Harry W Flynn; Craig M Greven; Avinash Pathengay; Darlene Miller; Robert F Sanke; Joseph Thorman
Journal:  Clin Ophthalmol       Date:  2013-08-27

10.  Intravitreal docosahexaenoic acid in a rabbit model: preclinical safety assessment.

Authors:  Rosa Dolz-Marco; Roberto Gallego-Pinazo; M Dolores Pinazo-Duran; Sheila Pons-Vázquez; Joan Carles Domingo-Pedro; Manuel Díaz-Llopis
Journal:  PLoS One       Date:  2014-05-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.